A Comparative Analysis of Serum and Serum-free Media for Generation of Clinical Grade DCs
- 1 July 2007
- journal article
- research article
- Published by Wolters Kluwer Health in Journal of Immunotherapy
- Vol. 30 (5) , 567-576
- https://doi.org/10.1097/cji.0b013e318046f396
Abstract
Dendritic cells (DCs) are the most potent antigen presenting cells and are therefore widely used in cancer immunotherapy. An optimal method for the generation of DCs for clinical use remains to be established. The aim of the study was to find a serum-free media (SFM) able to generate reproducible and functional cultures of DCs for clinical studies. We characterized immature and mature DCs cultured in SFM, CellGro DC and X-VIVO15, and serum media (SM), RPMI 1640+5% human serum or autologous serum. The expression of HLA-DR, CD86, CD83 was higher in SM-cultured DCs (SM-DCs) than SFM-derived DCs (SFM-DCs). Between SFM-DCs, CellGro-cultured DCs (CellGro-DCs) showed a higher expression and an improved up-regulation capacity of all molecules as compared with X-VIVO15-derived DCs (X-VIVO15-DCs). CellGro-DCs and SM-DCs showed a similar mannose receptor expression and related endocytic capacity tested by fluorescein isothiocyanate-dextran uptake. In contrast X-VIVO15-DCs expressed low levels of mannose receptor and were unable to endocyte fluorescein isothiocyanate-dextran. DCs cultured in all conditions stimulated a mix lymphocyte reaction, but CellGro-DCs and SM-DCs induced a more potent T-cell proliferation compared with X-VIVO15-DCs. Cytokine analysis showed that after maturation, all DC cultures produced IL-12p70 and IL-10 except for X-VIVO15-DCs which only produced the latter cytokine. SM-DCs and SFM-DCs induced a TH1 polarization in allogeneic naive T cells. In conclusion, a comparative analysis of DC performance generated in different conditions allows us to determine CellGro DC as the optimal medium for the generation of clinical grade DCs.Keywords
This publication has 47 references indexed in Scilit:
- Immune and Clinical Outcomes in Patients with Stage IV Melanoma Vaccinated with Peptide-Pulsed Dendritic Cells Derived From CD34+ Progenitors and Activated with Type I InterferonJournal of Immunotherapy, 2005
- Efficient migration of dendritic cells toward lymph node chemokines and induction of TH1 responses require maturation stimulus and apoptotic cell interactionBlood, 2005
- Stable T cell–dendritic cell interactions precede the development of both tolerance and immunity in vivoNature Immunology, 2005
- Variegation of the Immune Response with Dendritic Cells and Pathogen Recognition ReceptorsThe Journal of Immunology, 2005
- New developments in dendritic cell?based vaccinations: RNA translated into clinicsCancer Immunology, Immunotherapy, 2005
- Immunotherapy Via Dendritic CellsPublished by Springer Nature ,2005
- Transfer of antigen between migrating and lymph node-resident DCs in peripheral T-cell tolerance and immunityTrends in Immunology, 2004
- Dendritic cell immunotherapy: mapping the wayNature Medicine, 2004
- Generation of Carcinoembryonic Antigen (CEA)-Specific T-Cell Responses in HLA-A*0201 and HLA-A*2402 Late-Stage Colorectal Cancer Patients after Vaccination with Dendritic Cells Loaded with CEA PeptidesClinical Cancer Research, 2004
- Phase I/II study of treatment with dendritic cell vaccines in patients with disseminated melanomaCancer Immunology, Immunotherapy, 2004